Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Inhibitor Therapeutics, Inc. (INTI) had Income from Continuous Operations of $-0.66M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-0.66M |
|
-- |
|
-- |
|
$0.70M |
|
$-0.70M |
|
$0.04M |
|
$-0.66M |
|
$-0.66M |
|
$-0.66M |
|
|
Income from Continuous Operations |
$-0.66M |
$-0.66M |
|
$-0.66M |
|
$-0.70M |
|
$-0.70M |
|
172.57M |
|
172.57M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$3.83M |
|
-- |
|
$0.08M |
|
$3.91M |
|
$0.14M |
|
-- |
|
$3.05M |
|
$3.19M |
|
$0.72M |
|
$0.72M |
|
$0.72M |
|
172.57M |
|
| Cash Flow Statement Financials | |
$-1.87M |
|
-- |
|
-- |
|
$5.61M |
|
$3.74M |
|
$-1.87M |
|
$0.02M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
27.36 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.87M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-92.22% |
|
-92.22% |
|
-16.89% |
|
-92.22% |
|
$0.00 |
|
$-0.01 |
|
$-0.01 |
|